Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
cholangiocarcinoma with FGFR2 fusion or rearrangement |
| gptkbp:ATCCode |
L01EX23
|
| gptkbp:brand |
Truseltiq
|
| gptkbp:CASNumber |
872511-34-7
|
| gptkbp:developer |
Helsinn Healthcare
QED Therapeutics |
| gptkbp:hasMolecularFormula |
C26H31Cl2N5O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Infigratinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:PubChem_CID |
25154816
CHEMBL2036765 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
alopecia dry mouth hyperphosphatemia nail toxicity stomatitis |
| gptkbp:target |
gptkb:FGFR3
gptkb:FGFR1 gptkb:FGFR2 |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
gptkb:urothelial_carcinoma
cholangiocarcinoma |
| gptkbp:bfsParent |
gptkb:CD332
gptkb:CD333 |
| gptkbp:bfsLayer |
7
|